EVALUATION OF THE TESTOSTERONE-BOOSTING ACTIVITY OF TAXADROL® IN A RETIRED PROFESSIONAL BODYBUILDER

Guideline FDA

Lead Physician Dr. Shahram Shawn Gholami M.D. Urological Oncology

Lead Clinic Urology Associates of Silicon Valley

> Study Supervisor Jeff Golini

Study completed on September 30th, 2009

Over seeing laboratory

BioCeutical Research & Development Laboratory 2376 Main Street Room 14 Billings, MT 59105

> BRDL Study No. 1001-A

> > (1 of 2)

Introduction:

The study was performed to assess the short-term benefits and side effects of Taxadrol® in human beings when administered an oral dose at prescribe amounts. The study was intended to provide information on the potential health benefits and side effects of Taxadrol® for athletes. Data from this study may serve as a basis for classification and/or labeling of the test article. Data also will serve as validated marketing research that presents the case for the effectiveness of Test Charge®. The study was performed by BioCeutical Research & Development Laboratory at 2376 Main Street, Room 14, Billings, Montana. The protocol was signed by the Study Director on February 1st, 2007. The study was initiated with test article administration on May 1st, 2007 and concluded on September 30th, 2009.

History of Subject:

This male athlete is a retired professional bodybuilder, who during the course of his career took sports enhancing substances. Because of this use, his testosterone levels were very low and abnormal. Records provided to the testing coordinator, from this individual's doctor, reviled testosterone testing dating back to 2003. This body builder's testosterone levels during 2003 and 2006 ranged from 54 to 125 which required prescription testosterone therapy for health reasons.. The therapy helped stabilize his testosterone levels. The total serum testosterone after therapy ranged from 100 to 125 to ng/dl

Low testosterone levels or TD (testosterone deficiency) can lead to abnormalities in muscle and bone development, loss of vigor and energy, decreased vigor & sexual drive along with low sperm count.

Procedure:

Taxadrol® was administered to the subject at dosages of 30 mg per day taken sublingual.

Results:

Testosterone serum levels with therapy	9/21/06	125 ng/dl
Subject discontinues hormone therapy	3/01/07	
Subject starts Taxadrol® therapy	4/30/07	
Testosterone serum levels with Taxadrol®	9/13/07	320 ng/dl
	8/14/08	333 ng/dl
	9/14/09	400 ng/dl

Summary:

The subjects serum test osterone levels increased from 125 ng/dl on hormone therapy to 400 ng/dl on Taxadrol \mathbb{R}

Conclusion:

Taxadrol® raised the subjects testosterone levels dramatically over traditional hormone therapy with no side effects. Strength and size increases were reported along with decrease in body fat.

(2 of 2)